Lenalidomide

• MInimal residual Disease Adapted Strategy / IFM 2020-02 Pending
  2024-513889-19-00 Phase III 2 countries Intergroupe Francophone Du Myelome
• A phase II efficacy and safety study of cell-free circulating tumor DNA-guided commencement of second-line treatment in patients with DLBCL/… Pending
  2024-518275-64-00 Phase II 1 country Instytut Hematologii I Transfuzjologii
• Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM): A nationwide phase 2 trial of patients with smoldering and active multiple my… Pending
  2024-519353-11-00 Phase II 1 country Landspitali
• Lenalidomide versus methotrexate in difficult-to-treat cutaneous lupus erythematosus Pending
  2024-520089-70-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• Accelerate Improvement in Multiple Myeloma for Newly Diagnosed Transplant-Eligible Patients (AugMMent) Pending
  2025-523990-40-00 Phase III 1 country Universitaetsklinikum Heidelberg AöR
• PLUTO Pending
  2026-525211-14-00 Phase II 1 country Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
• A study to compare Efficacy, Safety and How the Body Absorbs, Distributes, and Eliminates of Subcutaneous CT-P44 and Darzalex Faspro in Comb… Recruiting
  2024-518588-36-00 Phase III 2 countries Celltrion Inc.
• A Study of Zanubrutinib Versus Lenalidomide in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma (MAHOGANY) Recruiting
  2022-502548-12-00 Phase III 14 countries BeOne Medicines AG
• A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants with Multiple Myeloma Receiving Etentamig (ABBV-… Recruiting
  2024-515770-27-00 Phase I/II 1 country AbbVie Deutschland GmbH & Co. KG
• A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratum… Recruiting
  2025-520897-21-00 Phase II/III 3 countries AbbVie Deutschland GmbH & Co. KG
• A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab… Recruiting
  2024-519827-16-00 Phase III 16 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.
• A Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) vs Investigator’s Choice in Participants… Recruiting
  2024-519152-82-00 Phase III 8 countries Celgene Corp.
• Response-adaptive to Epcoritamab In FIrst Relapse: A Phase II, response-adaptive, Open-Label, Multicenter Study to Evaluate the Efficacy of … Recruiting
  2024-514440-86-00 Phase II 1 country Fundacion Geltamo
• A phase 3, open-label, controlled, randomized study of newly diagnosed multiple myeloma treatment, designed to evaluate the efficacy and saf… Recruiting
  2024-516418-39-00 Phase III 1 country Intergroupe Francophone Du Myelome
• IFM2024-06 : A multi-center, open-label, phase 2 randomized study of elranatamab plus lenalidomide versus daratumumab plus lenalidomide as p… Recruiting
  2024-517325-43-00 Phase II 1 country Centre Hospitalier Universitaire De Nantes
• A Phase 2 Study evaluating Epcoritamab in subjects with relapsed and refractory primary diffuse large B-cell lymphoma of the CNS treated wit… Recruiting
  2023-505834-84-00 Phase II/III 1 country Lysarc
• Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1… Recruiting
  2023-508196-36-00 Phase II 5 countries Karolinska University Hospital
• A first time in man study to look at the safety of the experimental drug CCS1477 and what effects it has on cancers that affect the blood, b… Recruiting
  2024-519498-20-00 Phase I/II 1 country Cellcentric Limited
• Clinical trial for the use of a humanized CART directed against BCMA (ARI0002h) in patients with newly diagnosed primary plasma cell leukemi… Recruiting
  2024-515053-21-00 Phase II 1 country Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques Augus…
• Phase 3 study of belantamab mafodotin, lenalidomide, and dexamethasone (BRd) versus daratumumab, lenalidomide, and dexamethasone (DRd) in pa… Recruiting
  2024-516030-35-00 Phase III 11 countries Glaxosmithkline Research & Development Limited
• HOVON 170 DLBCL: ANTICIPATE: Prevention of ANThracycline-Induced Cardiac dysfunction by dexrazoxane In PATients with diffusE large B-cell ly… Recruiting
  2023-505377-32-00 Phase III 1 country Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)
• MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting
  2023-505436-35-00 Phase III 6 countries Lysarc
• FeAsiBility of a treatment free interval in newly diagnosed mUltiple myeLOma patients treated with DaratumUmab-Lenalidomide-DexamethaSone – … Recruiting
  2023-508586-33-00 Phase III 1 country Stichting Hemato-Oncologie voor Volwassenen Nederland (Hovon)
• A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezom… Recruiting
  2023-507632-20-00 Phase III 9 countries Emn Trial Office S.r.l. Impresa Sociale; European Myeloma Network B.V.

Showing 1–24 of 98 trials